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ABSTRACT The effector domain mutants of oncogenic
Ras, V12S35 Ras, V12G37 Ras, and V12C40 Ras were tested
for their abilities to mediate tumorigenic and metastatic
phenotypes in athymic nude mice when expressed in NIH 3T3
fibroblasts. All mutants displayed comparable tumorigenic
properties, but only the mutant that activates the Raf-
mitogen-activated protein kinase kinase (MEK)-extracellular
regulated kinase (ERK) 1y2 pathway, V12S35 Ras, induced
tumors in the experimental metastasis assay. Furthermore,
direct activation of the MEK-ERK1y2 pathway in NIH 3T3
cells by mos or a constitutively active form of MEK was
sufficient to induce metastasis whereas R-Ras, which fails to
activate the ERK1y2 pathway, is tumorigenic but nonmeta-
static. The subcutaneous tumors and lung metastases derived
from V12S35 Ras-transformed NIH 3T3 cells expressed
higher levels of activated ERK1y2 in culture when compared
with the parental cellular pool before injection, indicating that
selection for cells with higher levels of activated ERK1y2
occurred during tumor growth and metastasis. By contrast,
cells explanted from V12G37-Ras or V12C40-Ras-induced
tumors did not show changes in the level of ERK1y2 activation
when compared with the parental cells. When tumor-
explanted cell lines derived from each of the effector domain
mutants were passaged one additional time in vivo, all medi-
ated rapid tumor growth, but, again, only cells derived from
V12S35 Ras-tumors formed numerous metastatic lesions
within the lung. These results show that the metastatic
properties of the Ras effector domain mutants segregate, and
that, whereas Ras-mediated tumorigenicity can arise inde-
pendently of ERK1y2 activation, experimental metastasis
appears to require constitutive activation of the ERK1y2
pathway.
The precise molecular events leading to the acquisition of the
metastatic phenotype remain largely unclear. Members of the
Ras super family of small GTP-binding proteins have been
implicated in the regulation of diverse biological functions,
including tumor progression. Activating mutations in ras genes
are commonly found in a variety of human tumors, and, in
addition, oncogenic mutants of Ras confer both tumorigenic
and metastatic properties to rodent cells in culture, providing
a system for determining the molecular events necessary for
tumor progression (1). In its active GTP-bound state, Ras
activates a number of signaling pathways through its ability to
activate key effector proteins. The most extensively studied of
these is the mitogen-activated protein (MAP) kinase 1y2
pathway (2). Ras associates with and activates the serine kinase
Raf-1, which in turn phosphorylates the dual specific kinase
MEK (also known as MAP kinase kinase or MAPKK), which
in turn phosphorylates the MAP kinases ERK1 and 2 (for
extracellular regulated kinases 1 and 2). Activated MAP
kinases translocate to the nucleus whereby they modulate gene
expression (3, 4).
A large body of evidence suggests a central role for the
Raf-MEK-ERK1y2 pathway in a variety of Ras-mediated
responses, but more recent studies (2, 5) have implicated
Raf-independent pathways in diverse biological events medi-
ated by the Ras oncogene, including cytoskeletal reorganiza-
tion, gene expression, and cell cycle progression. For example,
members of the Rho family of small GTP-binding proteins
have been shown to act as key regulators of Ras-mediated
cytoskeletal modifications and proliferation (2, 6). In addition,
the Rho GTPases have been implicated in motility and inva-
sion (7–10), and it has been suggested that Rho may serve as
an essential mediator during tumor metastasis (11). However,
the precise Ras-mediated signaling pathways and downstream
genetic events key to the acquisition of the metastatic pheno-
type remain to be elucidated.
A region of the Ras protein known as the effector domain
(amino acids 32–40 in H-Ras) has been shown to be essential
for the interaction between Ras and a variety of effectors,
which in mammals include Raf-1, PI3-K (phosphatidylinositol
3-kinase), RasGAPs, Ral guanine nucleotide exchange factors,
MEK kinase 1, Rin1 and AF6yRsb1 (2, 12). Point mutations
within the effector domain of oncogenic ras generates mutants
deficient in specific effector function and therefore activation
of specific downstream signaling pathways (13). By using these
Ras effector domain mutants (V12S35 Ras, V12G37 Ras, and
V12C40 Ras), it was shown that Ras-mediated tumorigenic
transformation can occur independently of the Raf-MEK-
ERK1y2 pathway (13, 14). Here, we show that, although both
Raf-dependent and Raf-independent Ras signaling pathways
mediate tumor growth, the Raf-MEK-ERK1y2 pathway ap-
pears necessary for activity in experimental metastasis assays.
Thus, the Ras effector pathways mediating the tumorigenic
and metastatic activities can be segregated.
METHODS
Molecular Constructs, Cell Lines, and Transfections. All ras
expression constructs encode mutant versions of the trans-
forming human H-Ras (V12) protein. The pDCR-ras (V12),
pDCR-ras (V12,S35), pDCR-ras (V12, G37), and pDCR-ras
(V12, C40) mammalian constructs encode effector domain
mutants of H-Ras (V12) in which expression is under the
control of the cytomegalovirus promoter and in which the
protein product is HA-tagged at the N terminus (13, 14). The
R-Ras expression construct (V38 R-Ras) in the pMT-SM
plasmid was a kind gift from Alan Hall (University College of
London, United Kingdom). NIH 3T3 (490) cells were grown
in DMEM supplemented with 10% fetal bovine serum and
were maintained at 37°C in a humidified atmosphere of 10%
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CO2. NIH 3T3 cells transformed with the mouse mos oncogene
(15) and constitutively activated MEK (16) have been de-
scribed and were cultured as above.
DNA transfections were performed by using the DOTAP
reagent as per manufacturers instructions (Boehringer Mann-
heim) by using 10 mg of DNA per 100 mm culture dish. After
transfections, cells were placed under selection (400 mgyml
Geneticin), and multiple G418 resistant clones (.100) were
pooled together to establish each cell line used in subsequent
studies.
Western Blot Analysis and Immunoprecipitation. Cells
were treated as indicated and were lysed as described (17).
Protein samples (10 mg) in Laemmli buffer were resolved by
SDSyPAGE. After transfer to nitrocellulose, blots were
probed with the following primary antibodies: rabbit poly-
clonal a-Ha (Y11, Santa Cruz Biotechnology); rabbit poly-
clonal a-Raf-1 (C12, Santa Cruz Biotechnology); rabbit poly-
clonal a-phospho-MEK1y2 (New England Biolabs); rabbit
polyclonal a-MEK1y2 (Transduction Laboratories, Lexington,
KY); rabbit polyclonal a-phospho-ERK1y2 (Promega); mouse
monoclonal a-ERK1y2 (Zymed); rabbit polyclonal a-Met (SP
260, Santa Cruz Biotechnology); and mouse monoclonal
a-phosphotyrosine (4G10, Upstate Biotechnology, Lake
Placid, NY). After incubation with the appropriate peroxi-
dase-conjugated secondary antibody (Boehringer Mannheim),
proteins were visualized by using the enhanced chemilumines-
cence (ECL) system (Amersham).
Immunoprecipitations were performed as described (17) by
using 500 mg of cell lysates incubated overnight at 4°C with the
desired antibody (a-HA or a-Met). Resulting immune com-
plexes then were pelleted by using protein-A-agarose (Sigma),
were washed with lysis buffer, and were resuspended in
Laemmli buffer. Samples then were subjected to Western
blotting as described above.
In Vitro ERK1y2 Kinase Assay. The method for detecting
ERK1y2 activity in cells expressing the different Ras effector
domain mutants was adapted from that of Khosravi-Far et al.
(14). ERKs 1 and 2 were immunoprecipitated from cell lysates
as described above by using a mouse monoclonal anti-ERK1y2
antibody (Zymed; clone ERK-7D8). Immune complexes were
washed three times with lysis buffer and twice with kinase
buffer (25 mM Hepes, pH 7.2y100 mM NaCly5 mM MgCl2y1
mM DTTy0.1 mM sodium vanadatey10 mM ATPy0.1% BSAy
0.1% Triton-X-100). Each kinase reaction was carried out in
the presence of 4 mg myelin basic protein and 10 mCi of {g-32P}
ATP at 30°C for 30 minutes. The reactions were stopped by the
addition of 1y3 volume of 43 Laemmli buffer. The proteins
then were separated by 14% SDSyPAGE and were visualized
by autoradiography.
In Vivo Tumorigenicity and Metastasis Assays and Histo-
logical Analysis. The mice utilized in these experiments were
'4-week-old female athymic nudes (Ncr nuynu) that were
obtained from the animal protection area, National Cancer
Institute, Frederick Cancer Research and Development Cen-
ter, Frederick MD. Animal care was provided in accordance
with the procedures outlined in the Guide for the Care and Use
of Laboratory Animals (NIH Publication No. 86–23, 1985).
For the analysis of tumor growth and experimental metas-
tasis, 105 cells (0.1 ml) were injected s.c. and i.v., respectively,
into nude mice as described (18). Animals were killed when
they appeared distressed or after 14 weeks. Tumor-derived
cultures were obtained from s.c. grown tumors and lung
metastases after killing the animals, dissecting and mincing the
tumor tissue, and plating in DMEMy10% fetal bovine serum
medium containing 400 mgyml active Geneticin to select
against growth of host tissue.
For histological examination, gross necropsies were per-
formed on a representative selection of animals from each
group. Tissues were fixed in 10% buffered neutral formalin at
necropsy and were examined for gross lesions suggestive of
metastasis. Tissues and lesions were processed in paraffin,
were sectioned at 5 mm, and were stained with hematoxylin and
eosin. An additional 50-mm step section was made on the lung
block.
RESULTS
Characterization of Ras Effector Domain Mutants in NIH
3T3 (490) cells. NIH 3T3 cells transfected with the various
oncogenic Ras (V12) effector domain mutants were analyzed
for expression of HA-tagged Ras proteins by Western blot
analysis (Fig. 1A). The levels of expression were similar
between the three effector domain mutants used in these
studies (V12S35 Ras, V12G37 Ras, and V12C40 Ras; Fig. 1,
lanes 3, 4, and 5, respectively) and were notably higher than
that observed in cells transfected with the wild-type (wt) ras
oncogene (wt V12 Ras; Fig. 1, lane 2). These Ras effector
domain mutants were identified and characterized in part on
the basis of their differential association with the Raf-1
cytoplasmic kinase (13, 14). We, therefore, determined the
activity of the Raf-MEK-ERK1y2 pathway in NIH 3T3 (490)
cells expressing the different Ras mutants (Fig. 1 B–D). After
immunoprecipitation of the HA-tagged Ras effector domain
mutants and Western blotting for Raf-1, we detected a high
level of Ras-Raf-1 association (coprecipitation) in cells ex-
pressing wt V12 Ras (Fig. 1B, compare lanes 1 and 2).
FIG. 1. Characterization of the Ras-Raf-MEK-ERK1y2 pathway in
NIH 3T3 (490) cells transfected with vector alone (lane 1), wt V12 Ras
(lane 2), V12S35 Ras (lane 3), V12G37 Ras (lane 4) or V12C40 Ras
(lane 5). (A) Western blot analysis of HA-tagged Ras oncoproteins
showing comparable levels of expression in cell pools stably expressing
the different Ras effector domain mutants. The positions of the
HA-tagged Ras proteins are shown. (B) Ras-Raf-1 association (co-
precipitation) in cells expressing the different Ras effector domain
mutants. Cell lysates first were immunoprecipitated with an HA
antiserum, followed by anti-Raf-1 Western blotting. The positions of
p74Raf-1 and Ig heavy chains are indicated. (C) The levels of MEK
phosphorylation (activation) in cells expressing the different Ras
effector domain mutants were determined by Western blotting using
an antibody against only phosphorylated MEK1y2. Reprobing the blot
with an antibody that recognizes total MEK1y2 demonstrated the
same level of MEK1y2 expression in all samples (data not shown). The
positions of phospho-MEK1y2 are shown. (D) ERK1y2 activity in cells
expressing the different Ras effector domain mutants. ERK1y2 im-
munoprecipitates were used in an in vitro kinase assay with myelin
basic protein as a substrate in the presence of {g-32P}-ATP. The
position of phosphorylated myelin basic protein is indicated. The
positions of the relative molecular mass markers are shown through-
out.
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However, all of the Ras effector domain mutants displayed
significantly reduced Ras-Raf association (Fig. 1B, lanes 3–5),
as compared with wt V12 Ras. Both V12S35 Ras and V12G37
Ras displayed some Raf-1 association whereas none was
observed with the V12C40 Ras mutant. We next tested for
activation of MEK by using a phospho-specific MEK1y2
antibody that only recognizes the activated form of MEK.
Serum-starved cells expressing the wt V12 Ras protein dis-
played significantly elevated MEK phosphorylation when com-
pared with parental control cells (Fig. 1C, compare lanes 1 and
2). V12S35 Ras induced MEK phosphorylation above that of
control cells but not to the level observed with wt V12 Ras (Fig.
1C, lane 3) whereas neither V12G37 Ras (Fig. 1C, lane 4) or
V12C40 Ras (Fig. 1C, lane 5) showed significant MEK phos-
phorylation above control levels. Reprobing the blot with an
antibody against total MEK1y2 showed similar levels of MEK
expression in the different mutant cell lines (data not shown).
ERK1y2 activity was measured directly in the cells expressing
the different Ras effector domain mutants in an in vitro kinase
assay (Fig. 1D). Serum-starved NIH 3T3 (490) cells expressing
wt V12 Ras exhibited an '2.6-fold increase in ERK1y2 activity
toward a myelin basic protein substrate when compared with
control cells (Fig. 1D, lanes 1 and 2) whereas the V12S35 Ras
lysate showed modest ERK1y2 activity above parental cells
('1.4-fold increase; compare Fig. 1D, lanes 1 and 3). Cells
expressing either of the V12G37 (Fig. 1D, lane 4) or V12C40
(Fig. 1D, lane 5) Ras mutants showed only a very slight
increase above control cells. Similar results were obtained by
using an antibody specific for the phosphorylated (activated)
form of ERK1y2 (data not shown). These results show that,
similar to previous reports, the V12S35 Ras mutant retains
partial Raf-MEK-ERK1y2 activity whereas V12G37 Ras and
V12C40 Ras mutants are virtually inactive in this pathway
(refs. 13, 14, and 19; L.V.A., unpublished observations).
Raf-Dependent and Raf-Independent Pathways Contribute
to Ras-Mediated Tumorigenesis. To investigate the tumori-
genic properties of cells expressing the different Ras effector
domain mutants, we injected stably transfected cells s.c. into
athymic nude mice. All Ras effector domain mutant oncogenes
were tumorigenic when expressed in NIH 3T3 (490) cells, and
only slight differences were observed among the cell lines
expressing the various effector domain mutants (Table 1). The
V12G37 Ras mutant displayed slightly reduced tumorigenicity
when compared with the other mutants, and all effector
domain mutants displayed delayed latency periods for tumor
growth when compared with wt V12 Ras. The tumors induced
by the three Ras effector domain mutants grew in size at
comparable rates but slower than those induced by wt V12 Ras
(data not shown). These results suggest that Ras-mediated
NIH 3T3 tumorigenicity occurs through both Raf-dependent
and Raf-independent pathways and that multiple pathways
downstream of Ras are required for maximal tumorigenic
transformation (14).
Differential Abilities of Ras Effector Domain Mutants To
Mediate Experimental Metastasis. We investigated the ability
of cells expressing the various Ras effector domain mutants to
colonize the lung in experimental metastasis assays in athymic
nude mice. This assay at least measures extravasation and
colonization of tumor cells within the lung. In contrast to the
similar tumorigenic properties of the Ras effector domain
mutants, dramatic differences in the metastatic ability of cells
expressing these mutants were observed (Table 1). Cells
expressing wt V12 Ras rapidly formed experimental lung
metastasis, with the onset of disease occurring at '3–4 weeks.
Cells expressing the V12S35 Ras mutant formed lung metas-
tases in 100% of mice examined at 6–7 weeks (Table 1).
Examination of the lungs from the V12S35 Ras metastases
showed that they were of similar grade and morphology when
compared with wt V12 Ras (Fig. 2, compare B and C).
However, cells expressing either the V12G37 Ras or V12C40
Ras mutants failed to form experimental lung metastases even
after 14 weeks. All organs, including the lungs, from these mice
were examined and were found to be completely free of micro-
or macrometastases (Fig. 2 D and E). These results suggest that
activation of the ERK1y2 pathway is key to the development
of experimental lung metastases. To test this more directly, we
examined the metastatic activities of NIH 3T3 cells trans-
formed with either the Mos oncogene, a potent activator of
MEK (20), or a constitutively activated isoform of MEK (16).
Both Mos and activated MEK were highly tumorigenic and
metastatic in nude mice (Table 1). In addition, NIH 3T3 cells
Table 1. Tumorigenic and metastatic properties of NIH 3T3 cells
expressing Ras effector domain mutants
Transfected gene Tumorigenicity* Metastasis†
Vector alone (pDCR) 1y6 (8)‡ 0y7
V12 ras (wt) 6y6 (2) 9y9 (3–4)
V12S35 ras 6y6 (3) 7y7 (6–7)
V12G37 ras 7y8 (4)‡ 0y11
V12C40 ras 8y8 (3) 0y11
MEK 4y4 (3) 4y4 (5–6)
mos 4y4 (2) 4y4 (6–8)
R-Ras 3y3 (2–3) 0y3
*Number of mice with tumorsytotal number of mice injected s.c. after
9 weeks. Elapsed times (in weeks) after injection before visible
tumors appeared are shown in parentheses.
†Number of mice with lung metastasesytotal number of mice injected
i.v. after 14 weeks. Elapsed times (in weeks) after injection before
mice displayed signs of metastatic lung disease (labored breathing,
loss of weight) are shown in parentheses. The presence or absence of
lung metastases was verified by pathology.
‡Remaining mice developed tumors after 10–14 weeks.
FIG. 2. Histological analysis (hematoxylin–eosin staining) of par-
affin-embedded lung sections from mice after i.v. injection of cells
expressing the different Ras effector domain mutants. Diffuse meta-
static fibrosarcoma tumor tissue (T) can be observed in the lungs of
mice injected with cells expressing either wt V12 Ras (B) or V12S35
Ras (C) but not in those injected with cells expressing either control
vector (A), V12G37 Ras (D), or V12C40 Ras (E), the lungs from which
were completely free of metastatic lesions 14 weeks post injection.
(Bars 5 100 mm.)
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transformed by oncogenic R-Ras (V38 R-Ras), which does not
constitutively activate the ERK1y2 pathway in NIH 3T3 cells
(ref. 21; data not shown), were found to be highly tumorigenic
but not metastatic in experimental assays (Table 1). Taken
together, these results suggest that constitutive activation of
the ERK1y2 pathway is necessary and sufficient for the
acquisition of the metastatic phenotype in NIH 3T3 cells.
Increased ERK1y2 Activation in V12S35 Ras-Mediated
Tumors and Metastases. We investigated whether there would
be changes in the activation of the Raf-MEK-ERK1y2 pathway
in the tumors and metastases derived from NIH 3T3 cells
transformed by the different Ras effector domain mutants.
Tumor explants derived from s.c. tumors and experimental
lung metastases were established as independent cell lines. All
tumor- and metastases-derived cell lines were found to express
the same level of HA-tagged mutant Ras proteins as the
respective parental pools (Fig. 3A). However, a significant
increase in ERK1y2 phosphorylation was observed in both the
tumor- and metastases-explanted cell lines derived from the
V12S35 Ras mutant (Fig. 3B, lanes 3–5). This increase was
associated with an increased association between V12S35 Ras
and Raf-1 and an increase in ERK1y2 activity (Fig. 4). These
results show that V12S35 Ras transformed NIH 3T3 cells
expressing high levels of ERK1y2 activity are selected during
the formation of tumors and experimental lung metastases. In
contrast, ERK1y2 phosphorylation remained low in cell lines
derived from the s.c. tumors mediated by the other mutants
(V12G37 Ras and V12C40 Ras; Fig. 3B, lanes 6–9). This result
further supports the role of ERK1y2-independent signaling
pathways during Ras-mediated tumor growth.
Metastatic Properties of Tumor-Explanted Cell Lines Ex-
pressing Ras-Effector Domain Mutants. Cell lines derived
from explants of the s.c. tumors formed by NIH 3T3 cells
expressing the Ras effector domain mutants were reintroduced
into nude mice and again were examined for their tumorigenic
and metastatic properties. Under these conditions, all mutant
tumor cell lines caused rapid s.c. tumor growth comparable to
that of wt V12 Ras (Table 2). However, only the V12S35
Ras-explanted tumor cells formed numerous lung metastases
comparable to wt V12 Ras (Table 2 and Fig. 5) whereas after
7–9 weeks, the cell lines derived from V12G37 Ras and
V12C40 Ras-tumors also produced lung metastases (Table 2).
The number of metastatic lesions in the lungs were, however,
significantly lower when compared with those observed with
V12S35 Ras-tumor-explanted cells (Fig. 5). Tumor explants
from the V12G37 and V12C40 metastases (T-V12G37 Ras-M1
and T-V12C40 Ras-M1, respectively) were established and
analyzed further. Previous studies (18, 22–24) have shown that
expression of the Met receptor tyrosine kinase together with
its ligand, hepatocyte growth factoryscatter factor (HGFySF),
results in tumorigenic and metastatic phenotypes in a variety
of cell lines and that spontaneous NIH 3T3 metastatic variants
overexpress the Met receptor. We, therefore, analyzed the
tumor-derived V12G37 Ras and V12C40 Ras metastatic cell
FIG. 3. (A) Expression of HA-tagged Ras effector domain mutants
in cellular pools and derived s.c. tumors and experimental lung
metastases. (B) Activation of ERK1y2 in the tumors and metastases
derived from cells transformed by the different Ras effector domain
mutants. Western blots were probed with an antibody against the
HA-epitope (A) or one that recognizes only activated ERK1y2 (B).
Reprobing the blot in B with an antibody against total ERK1y2
demonstrated identical expression in all samples (not shown). The
positions of the HA-tagged Ras proteins and phosphorylated ERK1
and ERK2 are indicated. Each cell line is representative of .3 cell lines
examined. T, tumor; M, metastases.
FIG. 4. Ras-Raf-1 association (A) and ERK1y2 activity (B) in
control cells (lane 1), V12S35 Ras transformed cells (lane 2), and a
representative V12S35 Ras-derived metastatic cell line (lane 3).
Experiments were performed as described in the legend for Fig. 1 B
and D, respectively.
Table 2. Tumorigenic and metastatic properties of primary
tumor-explanted cells induced by Ras effector
domain mutants
Cell line Tumorigenicity* Metastasis†
T-V12S35 Ras 4y4 (2) 4y4 (4–5)
T-V12G37 Ras 4y4 (2–3) 3y4 (7–9)
T-V12C40 Ras 4y4 (2) 3y4 (7–8)
*Number of mice with tumorsytotal number of mice injected s.c.
Elapsed times (in weeks) after injection before visible tumors ap-
peared are shown in parentheses.
†Number of mice with lung metastasesytotal number of mice injected
i.v. after 14 weeks. Elapsed times (in weeks) after injection before
mice displayed signs of metastatic lung disease (labored breathing,
loss of weight) are shown in parentheses. The presence or absence of
lung metastases was verified by pathology.
FIG. 5. Photographs of representative lungs (n 5 4) of mice
injected i.v. with tumor-derived cell lines expressing V12S35 Ras (A),
V12G37 Ras (B), and V12C40 Ras (C) after 4 weeks. The values in
each panel represent the mean number of metastatic lesions observed
at necropsy. (Bar 5 0.5 cm.)
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lines for expression of the Met receptor. We found a significant
increase in Met expression in both metastatic cell lines when
compared with both the original cell pools and the tumor cell
lines that gave rise to the metastases (Fig. 6). Moreover, Met
was reactive with antiphosphotyrosine antibodies in the cell
lines derived from the metastases. We suspect that this results
from the endogenous expression of HGFySF in NIH 3T3 cells
(22) and that the higher level of Met autophosphorylation may
contribute to the metastatic phenotype of these cells.
DISCUSSION
A variety of tumor cell–host interactions are involved at
multiple levels of the metastatic cascade. The ras oncogene has
provided a suitable system for determining the events leading
to tumor metastasis by virtue of its ability to induce the
metastatic phenotype in a number of experimental systems (1).
Much attention has focused recently on the downstream
signaling and genetic events leading to the variety of cellular
effects mediated by the Ras oncogene. We have provided
evidence that the effector pathways mediating the tumorigenic
and metastatic activities of Ras can be segregated and that
activation of the Raf-MEK-ERK1y2 pathway appears neces-
sary for the acquisition of the metastatic phenotype in NIH
3T3 cells. The effector domain mutant of Ras, which retains
partial activation of the Raf-MEK-ERK1y2 pathway (V12S35
Ras), induces NIH 3T3 experimental metastasis whereas those
unable to activate this pathway directly (V12G37 Ras and
V12C40 Ras) fail to mediate metastasis (Table 1). Although
other effectors differentially regulated by these Ras effector
domain mutants also may participate in the induction of the
metastatic phenotype, we also show that R-Ras-transformed
NIH 3T3 cells are tumorigenic but nonmetastatic, coincidental
with the inability of oncogenic R-Ras to activate the ERK1y2
pathway (ref. 21; unpublished observations). Furthermore,
direct activation of the ERK1y2 pathway, by Mos or a con-
stitutively active mutant of MEK, is sufficient to mediate the
metastatic phenotype. In contrast to their different abilities to
mediate metastasis, all mutants induce comparable tumori-
genic properties when expressed in NIH 3T3 cells (Table 1). In
addition, although the tumors derived from V12S35 Ras-
transformed cells display elevated activation of ERK1y2, those
from V12G37 Ras- and V12C40 Ras-transformed cells showed
no increase in active ERK1y2. These data support a previous
finding (14) in which it was shown that Ras-mediated tumor-
igenic transformation occurs through both Raf-dependent and
Raf-independent pathways.
Because the abilities of the Ras effector domain mutants to
mediate the metastatic phenotype were determined in an
experimental assay in which cells are injected directly into the
blood stream, it follows that differences in their metastatic
propensity must relate to the latter stages of metastasis, i.e.,
extravasation, establishment, andyor secondary growth within
the lung. The precise function of the Raf-MEK-ERK1y2
pathway during these stages of metastasis remains unclear.
Oncogenic Ras has been shown to alter the expression profiles
of a number of gene products, some of which have been
associated with the metastatic phenotype (1). In support of our
findings, it was shown recently that activation of ERK1y2
regulates cell motility and migration across extracellular matrix
(25) and induces urokinase proteolytic activity (26). The latter
enzyme mediates degradation of the extracellular matrix,
which is important for the invasive stage of metastasis, and its
expression was shown recently to be reduced in squamous cell
carcinoma cell lines on treatment with the MEK inhibitor PD
098059, with concomitant reduced invasion in vitro (27). It is
interesting to note that it was shown recently that parental and
Ras-transformed cells extravasate equally well in a chicken
embryo chorioallantoic membrane model (28), suggesting that
the effector domain mutants of Ras may differentially regulate
postextravasation events, although this remains to be clarified.
Changes in cell shape mediated through modifications of the
cell cytoskeleton are likely to play vital roles in the develop-
ment of the invasiveymetastatic phenotype. We routinely
observe an increase in the spindle and refractile nature of
metastatic cell lines when compared with nonmetastatic cells,
and this increase appears to be associated with activation of the
ERK1y2 pathway (unpublished observations). It has been
shown that certain Ras-induced cytoskeletal changes, partic-
ularly membrane ruffling, are mediated through Rac (19, 29),
a member of the Rho family of small GTPases, which has been
implicated in cell invasion and metastasis (7–10). More re-
cently, the involvement of PI 3-kinase, a known effector of Ras,
in Ras-induced membrane ruffling has been demonstrated (30,
31). Of interest, of the three Ras effector domain mutants used
in our studies, only V12C40 Ras was shown to activate PI
3-kinase directly and to induce membrane ruffling (19, 31).
Thus, our data suggest that direct Ras-mediated activation of
PI3-K and subsequent Rac-induced membrane ruffling is not
sufficient to induce metastasis. Thus, the V12C40 Ras mutant
fails to mediate metastasis, as does R-Ras, which has been
shown to efficiently activate PI3-K (21). However, we cannot
exclude the possibility that indirect activation of these addi-
tional signaling pathways may contribute to the metastatic
phenotype.
It is believed widely that metastasis frequently occurs at the
late stages of tumor progression. Our results show that the
original pools of NIH 3T3 cells transformed by either V12G37
Ras or V12C40 Ras rapidly form s.c. tumors but cannot
colonize the lungs in experimental metastasis assays. However,
when tumor-derived cell lines are established and reintroduced
into nude mice, lung metastases eventually do form after a
significant delay (Table 2). These findings suggest that, during
the progressive growth of these tumors, a subset of cells
acquire metastatic properties. We have shown that these
metastatic variants overexpress the Met receptor tyrosine
kinase and display Met activation (Fig. 6). We have demon-
strated that autocrine Met-HGFySF activation results in both
tumorigenic and metastatic properties in a number of cell
systems including NIH 3T3 cells and that spontaneous meta-
static variants of NIH 3T3 cells overexpress the Met receptor
(18, 22–24). Because Met activates the Ras-ERK1y2 pathway
(32) on HGFySF stimulation, it is possible that the G37yC40
Ras metastatic variants have acquired an indirect means of
activating the ERK1y2 pathway through autocrine Met-
HGFySF signaling, thereby promoting metastasis. In this
regard, we did observe an increase in Ras-Raf-1 association
FIG. 6. Met expression (A) and Met tyrosine phosphorylation (B)
in parental pools (lanes 2 and 5), s.c. tumors (lanes 3 and 6), and
tumor-derived metastatic cell lines (lanes 4 and 7) expressing V12G37
Ras (lanes 2–4) and V12C40 Ras (lanes 5–7), along with that in control
cells (lane 1). After Met immunoprecipitation, Western blots were
probed sequentially for phospho-tyrosine (P-Tyr) and Met. The
positions of the p170Met precursor and the p140Met b-chain that
contains the tyrosine kinase domain and becomes phosphorylated on
activation (33) are shown.
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and a modest elevation in ERK1y2 activation in these meta-
static variants (unpublished observations).
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